

Giorgio Minotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5114121/publications.pdf>

Version: 2024-02-01

135
papers

12,119
citations

57758

44
h-index

25787

108
g-index

145
all docs

145
docs citations

145
times ranked

13848
citing authors

#	ARTICLE	IF	CITATIONS
1	Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. <i>Pharmacological Reviews</i> , 2004, 56, 185-229.	16.0	3,060
2	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801.	2.2	1,996
3	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	7.1	920
4	In Vivo Formation of 8-Epi-Prostaglandin F _{2α} Is Increased in Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3230-3235.	2.4	356
5	The role of iron in the initiation of lipid peroxidation. <i>Chemistry and Physics of Lipids</i> , 1987, 44, 191-208.	3.2	247
6	Redox cycling of iron and lipid peroxidation. <i>Lipids</i> , 1992, 27, 219-226.	1.7	247
7	An investigation into the mechanism of citrate ²⁻ -Fe ²⁺ -dependent lipid peroxidation. <i>Free Radical Biology and Medicine</i> , 1987, 3, 379-387.	2.9	217
8	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
9	Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. <i>FASEB Journal</i> , 1999, 13, 199-212.	0.5	183
10	The role of iron in oxygen radical mediated lipid peroxidation. <i>Chemico-Biological Interactions</i> , 1989, 71, 1-19.	4.0	175
11	Anthracycline cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2012, 11, S21-S36.	2.4	161
12	The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage ^{1,2} 1Guest Editor: Mario Comporti 2This article is part of a series of reviews on "Iron and Cellular Redox Status." The full list of papers may be found on the homepage of the journal.. <i>Free Radical Biology and Medicine</i> , 2002, 32, 1237-1243.	2.9	160
13	The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein ¹ in cytosolic fractions from human myocardium. <i>FASEB Journal</i> , 1998, 12, 541-552.	0.5	147
14	Doxorubicin Metabolism and Toxicity in Human Myocardium: A Role of Cytoplasmic Deglycosidation and Carbonyl Reduction. <i>Chemical Research in Toxicology</i> , 2000, 13, 414-420.	3.3	147
15	Sources and role of iron in lipid peroxidation. <i>Chemical Research in Toxicology</i> , 1993, 6, 134-146.	3.3	146
16	Cardiotoxicity of Antitumor Drugs. <i>Chemical Research in Toxicology</i> , 2008, 21, 978-989.	3.3	143
17	Superoxide and hydrogen peroxide ¹ -dependent inhibition of iron regulatory protein activity: a protective stratagem against oxidative injury. <i>FASEB Journal</i> , 1996, 10, 1326-1335.	0.5	128
18	Antioxidant Properties of 2,3-Dimethoxy-5-methyl- 6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone). <i>Chemical Research in Toxicology</i> , 1998, 11, 54-63.	3.3	107

#	ARTICLE	IF	CITATIONS
19	Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. <i>Cardiovascular Toxicology</i> , 2007, 7, 67-71.	2.7	107
20	Iron Regulatory Proteins: From Molecular Mechanisms to Drug Development. <i>Antioxidants and Redox Signaling</i> , 2010, 13, 1593-1616.	5.4	103
21	Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms. <i>Methods in Enzymology</i> , 2004, 378, 340-361.	1.0	101
22	Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart. <i>Journal of Biological Chemistry</i> , 2006, 281, 10990-11001.	3.4	88
23	Pharmacological Foundations of Cardio-Oncology. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 2-8.	2.5	81
24	Doxorubicin Paradoxically Protects Cardiomyocytes against Iron-mediated Toxicity. <i>Journal of Biological Chemistry</i> , 2004, 279, 13738-13745.	3.4	74
25	An introduction to the metabolic determinants of anthracycline cardiotoxicity. <i>Cardiovascular Toxicology</i> , 2007, 7, 80-85.	2.7	73
26	Human Heart Cytosolic Reductases and Anthracycline Cardiotoxicity. <i>IUBMB Life</i> , 2001, 52, 83-88.	3.4	71
27	Anthracycline Metabolism and Toxicity in Human Myocardium: Comparisons between Doxorubicin, Epirubicin, and a Novel Disaccharide Analogue with a Reduced Level of Formation and [4Fe-4S] Reactivity of Its Secondary Alcohol Metabolite. <i>Chemical Research in Toxicology</i> , 2000, 13, 1336-1341.	3.3	68
28	Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 424-433.	2.5	63
29	Nitric Oxide and Peroxynitrite Activate the Iron Regulatory Protein-1 of J774A.1 Macrophages by Direct Disassembly of the Fe ²⁺ S Cluster of Cytoplasmic Aconitase. <i>Biochemistry</i> , 2002, 41, 7435-7442.	2.5	62
30	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 2290-2309.	7.1	62
31	Anthracycline Degradation in Cardiomyocytes: A Journey to Oxidative Survival. <i>Chemical Research in Toxicology</i> , 2010, 23, 6-10.	3.3	59
32	Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. <i>Biochemical Pharmacology</i> , 2003, 66, 989-998.	4.4	58
33	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	1.7	55
34	Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. <i>Molecular Brain Research</i> , 1997, 50, 267-276.	2.3	53
35	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1219-1238.	2.4	52
36	Membrane Alterations in Cancer Cells... <i>Annals of the New York Academy of Sciences</i> , 1986, 488, 468-480.	3.8	52

#	ARTICLE	IF	CITATIONS
37	Adriamycin-dependent release of iron from microsomal membranes. Archives of Biochemistry and Biophysics, 1989, 268, 398-403.	3.0	51
38	NADPH- and adriamycin-dependent microsomal release of iron and lipid peroxidation. Archives of Biochemistry and Biophysics, 1990, 277, 268-276.	3.0	51
39	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmunity Reviews, 2011, 10, 631-635.	5.8	50
40	The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 467-478.	2.5	50
41	Early diagnosis of acute coronary syndrome. European Heart Journal, 2017, 38, 3049-3055.	2.2	50
42	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Annals of Hematology, 2017, 96, 549-558.	1.8	48
43	Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. British Journal of Pharmacology, 2003, 139, 641-651.	5.4	44
44	Pharmacology at Work for Cardio-Oncology: Ranolazine to Treat Early Cardiotoxicity Induced by Antitumor Drugs. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 343-349.	2.5	44
45	The concomitant management of cancer therapy and cardiac therapy. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2727-2737.	2.6	43
46	In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity. Cell Biology and Toxicology, 2007, 23, 49-62.	5.3	41
47	Superoxide-dependent lipid peroxidation and vitamin E content of microsomes from hepatomas with different growth rates. Archives of Biochemistry and Biophysics, 1985, 238, 588-595.	3.0	39
48	Cytochrome P-450 deficiency and resistance to t-butyl hydroperoxide of hepatoma microsomal lipid peroxidation. Lipids and Lipid Metabolism, 1986, 876, 220-225.	2.6	39
49	Doxorubicin Degradation in Cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 408-419.	2.5	38
50	Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 790-800.	2.5	35
51	Membrane Alterations in Cancer Cells:.. Annals of the New York Academy of Sciences, 1986, 488, 468-480.	3.8	34
52	Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence. Progress in Pediatric Cardiology, 2014, 36, 39-49.	0.4	34
53	Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. British Journal of Pharmacology, 2001, 134, 1271-1278.	5.4	32
54	Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation:Â Implications for Cardiotoxicity of Anticancer Anthracyclines. Chemical Research in Toxicology, 2002, 15, 1179-1189.	3.3	32

#	ARTICLE	IF	CITATIONS
55	Superoxide-dependent redox cycling of citrate-Fe ³⁺ : Evidence for a superoxide dismutaselike activity. Archives of Biochemistry and Biophysics, 1987, 253, 257-267.	3.0	31
56	The role of an endogenous nonheme iron in microsomal redox reactions. Archives of Biochemistry and Biophysics, 1992, 297, 189-198.	3.0	31
57	Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids. Journal of Biological Chemistry, 2004, 279, 5088-5099.	3.4	31
58	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. II. Amrubicin Shows Metabolic Advantages over Doxorubicin and Epirubicin. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 474-483.	2.5	29
59	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	329.8	29
60	Effect of Reactive Oxygen Species on Iron Regulatory Protein Activity. Annals of the New York Academy of Sciences, 1998, 851, 179-186.	3.8	28
61	Anthracycline Cardiotoxicity. Topics in Current Chemistry, 2007, 283, 21-44.	4.0	26
62	tert-Butyl hydroperoxide-dependent microsomal release of iron and lipid peroxidation. Archives of Biochemistry and Biophysics, 1989, 273, 137-143.	3.0	25
63	tert-Butyl hydroperoxide-dependent microsomal release of iron and lipid peroxidation. Archives of Biochemistry and Biophysics, 1989, 273, 144-147.	3.0	25
64	Heart Rate reduction by Ivabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. Clinical Research in Cardiology, 2017, 106, 69-75.	3.3	25
65	Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. Chemotherapy, 2018, 63, 55-63.	1.6	23
66	Cardiotoxic effects of anthracycline-taxane combinations. Expert Opinion on Drug Safety, 2003, 2, 59-71.	2.4	21
67	Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 175-184.	2.5	21
68	Anthracyclines. Cancer Chemotherapy and Biological Response Modifiers, 2003, , 29-40.	0.5	21
69	Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines. Chemical Research in Toxicology, 2016, 29, 1270-1278.	3.3	20
70	Metals and Membrane Lipid Damage by Oxy-Radicals. Annals of the New York Academy of Sciences, 1988, 551, 34-44.	3.8	18
71	Pharmacokinetics of Pegylated Liposomal Doxorubicin Administered by Intraoperative Hyperthermic Intraperitoneal Chemotherapy to Patients with Advanced Ovarian Cancer and Peritoneal Carcinomatosis. Drug Metabolism and Disposition, 2012, 40, 2365-2373.	3.3	18
72	Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases. Expert Review of Hematology, 2021, 14, 537-546.	2.2	17

#	ARTICLE	IF	CITATIONS
73	Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Seminars in Oncology, 2019, 46, 397-402.	2.2	16
74	Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 263-270.	2.5	15
75	Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 323-331.	2.5	15
76	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori, 2011, 97, 690-2.	1.1	15
77	Possible Sources of Iron for Lipid Peroxidation. Free Radical Research Communications, 1991, 12, 99-106.	1.8	14
78	O ₂ ˙ dependent lipid peroxidation does not affect the molecular order in hepatoma microsomes. FEBS Letters, 1986, 198, 301-306.	2.8	13
79	Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Future Cardiology, 2015, 11, 363-366.	1.2	13
80	Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 197-205.	2.5	13
81	ecancermedalscience. Ecancermedalscience, 2014, 8, 433.	1.1	12
82	Microsomal iron-dependent NADPH oxidation: Evidence for the involvement of membrane-bound nonheme iron in NADPH oxidation by rat heart microsomes. Archives of Biochemistry and Biophysics, 1990, 282, 270-274.	3.0	12
83	Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103074.	4.4	12
84	Acute Heart Failure 29 Years After Treatment for Childhood Cancer. JACC: CardioOncology, 2020, 2, 316-319.	4.0	12
85	Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 177-190.	2.5	12
86	Reactions of Adriamycin with Microsomal Iron and Lipids. Free Radical Research Communications, 1989, 7, 143-148.	1.8	11
87	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. I. Amrubicin Accumulates to a Lower Level than Doxorubicin or Epirubicin. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 464-473.	2.5	11
88	Pixantrone: novel mode of action and clinical readouts. Expert Review of Hematology, 2018, 11, 587-596.	2.2	11
89	Lipid Composition, Physical State, and Lipid Peroxidation of Tumor Membranes. Toxicologic Pathology, 1984, 12, 324-330.	1.8	10
90	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert Opinion on Drug Safety, 2018, 17, 623-628.	2.4	10

#	ARTICLE	IF	CITATIONS
91	Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 158-168.	2.5	10
92	Cardio-oncological management of patients. <i>Seminars in Oncology</i> , 2019, 46, 408-413.	2.2	10
93	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. <i>Chemotherapy</i> , 2021, 66, 47-52.	1.6	10
94	Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection. <i>Clinical Cancer Research</i> , 2021, 27, 3809-3811.	7.0	10
95	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. <i>European Journal of Haematology</i> , 2016, 97, 554-561.	2.2	9
96	Cancer drugs and QT prolongation: weighing risk against benefit. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1099-1102.	2.4	9
97	The anthracyclines: When good things go bad. <i>Cardiovascular Toxicology</i> , 2007, 7, 53-55.	2.7	8
98	Isavuconazole: Case Report and Pharmacokinetic Considerations. <i>Chemotherapy</i> , 2018, 63, 253-256.	1.6	8
99	Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab. <i>Current Cardiology Reports</i> , 2019, 21, 33.	2.9	8
100	Cardiovascular events in cancer survivors. <i>Seminars in Oncology</i> , 2019, 46, 426-432.	2.2	8
101	Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e74-e76.	3.0	8
102	Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox. <i>Cardiovascular Toxicology</i> , 2014, 14, 387-392.	2.7	7
103	Efficacy and safety of low dose ponatinib in a case of Philadelphia-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 187, e15-e17.	2.5	7
104	Treatment specific toxicities: Hormones, antihormones, radiation therapy. <i>Seminars in Oncology</i> , 2019, 46, 414-420.	2.2	7
105	From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction. <i>JACC: CardioOncology</i> , 2022, 4, 139-140.	4.0	7
106	Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials. <i>American Journal of Therapeutics</i> , 2022, 29, e199-e204.	0.9	6
107	4-Epidoxorubicin To Re-explore Anthracycline Degradation in Cardiomyocytes. <i>Chemical Research in Toxicology</i> , 2009, 22, 978-983.	3.3	5
108	Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological Appraisal. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 231-239.	2.5	5

#	ARTICLE	IF	CITATIONS
109	Managing cardiac risk factors in oncology clinical trials. Texas Heart Institute Journal, 2011, 38, 266-7.	0.3	5
110	Anthracyclines. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 29-40.	0.5	5
111	Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Advances in Pharmacology, 2022, , .	2.0	5
112	Restoration of hydroperoxide-dependent lipid peroxidation by 3-methylcholanthrene induction of cytochrome P-448 in hepatoma microsomes. FEBS Letters, 1986, 209, 305-310.	2.8	4
113	The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 518-527.	2.5	4
114	Safety and tolerability of a novel oral nutritional supplement in healthy volunteers. Clinical Nutrition, 2021, 40, 946-955.	5.0	4
115	What is cardiotoxicity?. Progress in Pediatric Cardiology, 2014, 36, 3-6.	0.4	3
116	An Invitation from the Editors of Cardio-Oncology. Cardio-Oncology, 2015, 1, 2.	1.7	3
117	The International Cardioncology Societyâ€œONE trial: Not all that glitters is for cardioncologists only. European Journal of Cancer, 2018, 97, 27-29.	2.8	3
118	Old and new directions of Cardio-Oncology. Seminars in Oncology, 2019, 46, 395-396.	2.2	3
119	In Â®Entresto we trust. Cardio-Oncology, 2020, 6, 25.	1.7	3
120	Matters of the Heart: The Case of TNFÂ®-Targeting Drugs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 79-87.	3.4	3
121	Development of a TumorÂ®-Specific Photoactivatable Doxorubicin Prodrug. Photochemistry and Photobiology, 2013, 89, 1009-1010.	2.5	2
122	Do You Know Pixantrone?. Chemotherapy, 2017, 62, 192-193.	1.6	2
123	Anthracyclines. Cancer Chemotherapy and Biological Response Modifiers, 2002, 20, 59-69.	0.5	2
124	Beyond Poisons and Problems: Toxicology in Italy. Chemical Research in Toxicology, 2008, 21, 771-774.	3.3	1
125	Helping the cardio-oncologist: from real life to guidelines. Seminars in Oncology, 2019, 46, 433-436.	2.2	1
126	The Reality of Pixantrone in Real Life. Acta Haematologica, 2021, 144, 244-245.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Chemotherapy</i> , 2020, 65, 35-41.	1.6	1
128	Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 381, 266-273.	2.5	1
129	New frontiers in Cardio-Oncology. <i>Progress in Pediatric Cardiology</i> , 2014, 36, 1-2.	0.4	0
130	The Second Special Cardio-Oncology Issue of <i>Progress in Pediatric Cardiology</i> : Closing remarks and hopes for the future. <i>Progress in Pediatric Cardiology</i> , 2015, 39, 57.	0.4	0
131	Quo Vadis COVID? Lessons from a Focus Topic Issue of <i>Chemotherapy</i> . <i>Chemotherapy</i> , 2021, 66, 1-2.	1.6	0
132	Biochemical and Pharmacological Properties of Coenzyme Q Analogs. <i>Modern Nutrition</i> , 2000, , 151-160.	0.1	0
133	Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs. <i>Drug Design Reviews Online</i> , 2005, 2, 267-276.	0.7	0
134	Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment. <i>Blood</i> , 2011, 118, 4966-4966.	1.4	0
135	Risk of Myocardial Infarction in Patients Treated With 5-Fluorouracil. <i>JACC: CardioOncology</i> , 2021, 3, 734-736.	4.0	0